Sirona Biochem Corp V.SBM

Wanbang phase 1 results

[wexworth]

Like Sernova, if/when they release their sglt2 results and provide hard facts in the release that point to how well/safe the inhibitor is, then I would expect a strong market reaction and newly established attention from more than just Johnson and Johnson.

[MirrorWorldMan]

As long as no toes are lost from amputation in phase 3 and CV/Renal endpoint data matches Empa or Cana. That will take years, otherwise just another MeeToo SGLT2. Howie took waaaay too long to even get this into phase 1. The opportunity has passed for those that know the Diabetes space. Unless maybe if they combine it with a DPP4 and Metformin. Otherwise another sunken cost...

[wexworth]

So outperforming a standard sglt2 inhibitor doesn't count?hmmm, and what about those billions of fat diabetics pets? 

[MirrorWorldMan]

SGLT2 efficacy is irrelevant without endpoint data. Look it up. Thats why so many big Pharma shelved theirs, even aftet FDA approval (like Merck etc). Too expensive to conduct mandatory FDA trials to prove end organ protection. Anyone from thr pharma industry can tell you that. Do you DD. 

[MirrorWorldMan]

Increased efficacy has also been associated with increased amputation in the SGLT2 CV/Renal trials. So, do your DD

[Nitrodouglas]

Thats when Hemostemix comes into play in saving limbs from amputation. 83% of folks in that trial so far have recovered their limbs through their blood stem cell tech. They'll releasing phase 2 midpoint data much like Sernova late February according to the Ceo. Could also go boom, cheaper too. Sirona's geared and trial data from China and 1067 .4 will get attention especially once we get a

[pointer]

This post has been removed in accordance with Community Policy

[wexworth]

And that is why I used it. If is part A of the question out there.